Clinical Trials on Plasma Volume in New Zealand

Total 904 results

Hospital for Special Surgery, New York

Completed

Blood Volume Analysis of Total Hip Arthroplasty Patients Under Hypotensive Anesthesia

Blood Volume Analysis

United States
Columbia University

Completed

Effects of Desflurane and Propofol During Lung Volume Reduction Surgery

Lung Volume Reduction Surgery

United States
Galderma R&D

Completed

Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand

Volume Deficit in the Hand

United States
Rigshospitalet, Denmark

Completed

Study of the Natural Variation in Strokevolume

Stroke Volume Variation

Denmark
Merz North America, Inc.

Completed

A Pilot Study to Assess the Effectiveness and Safety of Belotero Balance® Injection for Volume Augmentation of the Infraorbital Hollow

Correction of Volume Loss in the Infraorbital Hollow Area

United States
Croma-Pharma GmbH

Active, not recruiting

Saypha® VOLUME Lidocaine for Midface Augmentation (VOLIDO)

Moderate to Severe Midface Volume Deficit

United States
Merz North America, Inc.

Completed

Radiesse® Safety Study For the Treatment of Hands

Volume Loss in the Dorsum of the Hand

United States
Galderma R&D

Active, not recruiting

A Study to Evaluate the Effects for Midface Improvement When Pairing a Biostimulator With a Skincare Regimen

Photodamaged Skin | Volume Deficiency of the Midface

United States
Merz North America, Inc.

Completed

Evaluation of Effectiveness and Safety of Belotero Balance® (+) Lidocaine for Volume Augmentation of the Infraorbital Hollow

Volume Loss in the Infraorbital Hollow Area

United States, Puerto Rico
Medicis Global Service Corporation

Unknown

Efficacy and Safety of Perlane-L in the Correction of Midface Volume Deficit

Facial Volume

United States
Rajiv Gandhi Cancer Institute & Research Center...

Completed

Preoperative Ultrasound Guided Evaluation of SVC-CI and IVC -CI as Predictors of Hypotension After Induction of Anaesthesia in Major Onco-surgery (SVC IVC CI)

Total Fluid Volume Decreased

India
Allergan

Completed

A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula

Age-related Volume Deficit in the Mid-face

United States
Sequana Medical N.V.

Recruiting

Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 (MOJAVE)

Heart Failure | Volume Overload

United States
Yale University

Completed

Zero Sodium Peritoneal Dialysate Protocol Pilot Study

Potential Applications for Heart Failure | Volume Overload

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, New Zealand
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
CardioKine Inc.
Biogen; Cardiokine Biopharma, LLC

Completed

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

Hyponatremia With Normal Extracellular Fluid Volume

United States, Canada, Germany, India, Poland, Belgium
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Roswell Park Cancer Institute
Celgene

Active, not recruiting

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Plasma Cell Myeloma | Partial Response of Multiple Myeloma or Plasma Cell Leukemia

United States
Roswell Park Cancer Institute

Recruiting

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Immune Control

Completed

Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
VA New York Harbor Healthcare System
Daxor Corporation

Completed

Blood Volume Analysis and Renal Outcomes in Hemodialysis

Kidney Failure | End Stage Renal Failure on Dialysis | Actual Impaired Fluid Volume

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Roswell Park Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Roswell Park Cancer Institute

Terminated

Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

Multiple Myeloma and Plasma Cell Neoplasm

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Galderma R&D

Recruiting

Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies

Weight Loss | Skin Laxity | Photoaging | Photodamaged Skin | Volume Deficiency of the Midface

United States
Roswell Park Cancer Institute

Completed

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Roswell Park Cancer Institute

Completed

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Maryland, Baltimore
National Cancer Institute (NCI); University of Maryland Greenebaum Cancer Center

Completed

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Genta Incorporated

Completed

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
AO Innovation Translation Center
AO Foundation, AO Spine

Recruiting

Primary Tumor Research and Outcomes Network (PTRON)

Spinal Column Tumor

United States, Canada, Italy, Australia, China, Germany, Hungary, Japan, United Kingdom
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
LifeTime Pharmaceuticals

Unknown

Beta Alethine in Treating Patients With Myeloma

Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
State University of New York at Buffalo

Completed

Food Reinforcement, Weight Status, and Energy Density

Reinforcing Value of Food

United States

Clinical Trials on Plasma Volume in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations